After obesity, Eli Lilly is set for a big neurosciences push

{
  "signal_id": "df762a81-54bd-2ed7-aa9d-98abf218f0d2",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-29T06:20:57+00:00",
  "company": {
    "name": "Eli Lilly",
    "domain": "lilly.com"
  },
  "data": {
    "url": "https://pharma.economictimes.indiatimes.com/news/pharma-industry/after-obesity-eli-lilly-is-set-for-a-big-neurosciences-push/135292871",
    "title": "After obesity, Eli Lilly is set for a big neurosciences push - pharma.economictimes.indiatimes.com",
    "excerpt": "Mumbai: Blockbuster weight-loss and anti-diabetes drugs Mounjaro and Zepbound (tirzepatide) have catapulted US-headquartered Eli Lilly into the elite league of companies with a market capitalisation of more than $1 trillion. For its next phase of growth, the company is bolstering its research into neurosciences , primarily to treat conditions ranging from Alzheimer’s disease and sleep-wake disorders to psychiatry, substance use and non-opioid pain. Company executives said that Lormalzi (donanemab, branded as Kisunla in the US), which was approved by the US Food and Drug Administration in 2024, is now being tested in a large clinical trial of nearly 3,000 volunteers who may have amyloid plaque in their brain but have not yet presented with cognitive symptoms of Alzheimer’s disease. Advt “We'll most likely (have a) read-out sometime in 2027… That’s when we will see: is it beneficial to clear the plaque out of the brain before you get symptoms? And if you do so, would it delay the onset of the disease,” Patrik Jonsson, president, Lilly International, told ET in an exclusive interview, emphasising the need for an early diagnosis to minimise the damage. A widely reported form of dementia, Alzheimer’s disease is a progressive brain disorder that affects memory and thinking abilities, eventually impacting patients’ quality of life and making them entirely dependent on younger...",
    "product": "remternetug",
    "summary": "Eli Lilly is developing remternetug, a phase III investigational amyloid-targeting therapy for subcutaneous delivery to treat Alzheimer's disease.",
    "planning": true,
    "image_url": "https://etimg.etb2bimg.com/thumb/msid-135292871,imgsize-794440,width-1200,height=627,overlay-etpharma,resizemode-75/news/pharma-industry/after-obesity-eli-lilly-is-set-for-a-big-neurosciences-push.jpg",
    "confidence": 0.85,
    "product_data": {
      "name": "remternetug",
      "full_text": "remternetug, a phase III investigational amyloid-targeting therapy for subcutaneous delivery",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-29T06:20:57Z",
    "article_sentence": "Besides donanumab, Eli Lilly is working on remternetug, a phase III investigational amyloid-targeting therapy for subcutaneous delivery."
  }
}

curl https://signals.autobound.ai/v1/signals/df762a81-54bd-2ed7-aa9d-98abf218f0d2 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"lilly.com","limit":20}'